TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$4.34
0.03 (0.58%)
▲
5d:
+0.35%
30d:
-6.57%
90d:
-21.18%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 21, 2026
Smart Money Accumulation
TSHA is down 7.5% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 202 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TSHA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $4.33, which is considered slightly low relative to its 30-day fair value range of $4.31 to $4.68.
Technical Outlook: Technically, TSHA is in a uptrend. Immediate support is located at $4.03, while resistance sits at $4.62.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.36 (+163.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TSHA is in a uptrend. Immediate support is located at $4.03, while resistance sits at $4.62.
Market Sentiment: TSHA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.36 (+163.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.31 -
$4.68
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 163.5% below Wall St target ($11.36)
Fair Price Analysis
30-Day Fair Range
$4.31 -
$4.68
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.03
Resistance Level
$4.62
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.30
Wall Street Target
$11.36
(+163.5%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: April 02, 2026 12:44 PM ET
Data refreshes hourly during market hours. Next update: 1:44 PM
Data refreshes hourly during market hours. Next update: 1:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Kamran Alam
SELL
1655 shares
2026-02-04
Kamran Alam
SELL
23849 shares
2026-01-26
Sean P Nolan
SELL
41312 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 66 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$100 | 57 HOLD |
